Cardiac myosin light chain phosphorylation and inotropic effects of a biased ligand, TRV120023, in a dilated cardiomyopathy model

Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure

(2015) Miki Nonaka et al.   BRITISH JOURNAL OF PHARMACOLOGY

Advances in Clinical Cardiology

(2014) Andrew H. McNeice et al.   ADVANCES IN THERAPY

The β-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calcium

(2013) Michelle M. Monasky et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Familial dilated cardiomyopathy mutations uncouple troponin I phosphorylation from changes in myofibrillar Ca2+ sensitivity

(2013) Massimiliano Memo et al.   CARDIOVASCULAR RESEARCH

2013 ACCF/AHA Guideline for the Management of Heart Failure

(2013) Clyde W. Yancy et al.   CIRCULATION

First Clinical Experience with TRV027: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

(2013) David G. Soergel et al.   JOURNAL OF CLINICAL PHARMACOLOGY

β-Arrestin Regulation of Myosin Light Chain Phosphorylation Promotes AT1aR-mediated Cell Contraction and Migration

(2013) Elie Simard et al.   PLoS One

Getting the skinny on thick filament regulation in cardiac muscle biology and disease

(2013) Farah Sheikh et al.   TRENDS IN CARDIOVASCULAR MEDICINE

β-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury

(2012) Ki-Seok Kim et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Mouse and computational models link Mlc2v dephosphorylation to altered myosin kinetics in early cardiac disease

(2012) Farah Sheikh et al.   JOURNAL OF CLINICAL INVESTIGATION

The significance of regulatory light chain phosphorylation in cardiac physiology

(2011) Sarah B. Scruggs et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure

(2011) F. I. Malik et al.   SCIENCE

Troglitazone stimulates β-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor

(2010) Douglas G. Tilley et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cardiac Myosin Light Chain Kinase Is Necessary for Myosin Regulatory Light Chain Phosphorylation and Cardiac Performancein Vivo

(2010) Peiguo Ding et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Selectively Engaging  -Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance

(2010) J. D. Violin et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Differential roles of regulatory light chain and myosin binding protein-C phosphorylations in the modulation of cardiac force development

(2010) Brett A. Colson et al.   JOURNAL OF PHYSIOLOGY-LONDON

Familial Dilated Cardiomyopathy Caused by an Alpha-Tropomyosin Mutation

(2010) Neal K. Lakdawala et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The Angiotensin II Type 1 Receptor Induces Membrane Blebbing by Coupling to Rho A, Rho Kinase, and Myosin Light Chain Kinase

(2010) C. M. Godin et al.   MOLECULAR PHARMACOLOGY

Overexpression of Myosin Phosphatase Reduces Ca2+ Sensitivity of Contraction and Impairs Cardiac Function

(2009) Hideo Mizutani et al.   CIRCULATION JOURNAL

Identification of Cardiac-Specific Myosin Light Chain Kinase

(2008) Jason Y. Chan et al.   CIRCULATION RESEARCH

Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats

(2008) Pál Pacher et al.   Nature Protocols